Morr F 5% Topical Solution for Effective Androgenetic Alopecia Management
| Product dosage: 60 ml | |||
|---|---|---|---|
| Package (num) | Per sprayer | Price | Buy |
| 1 | $100.87 | $100.87 (0%) | 🛒 Add to cart |
| 2 | $83.22 | $201.73 $166.43 (18%) | 🛒 Add to cart |
| 3 | $73.97 | $302.60 $221.91 (27%) | 🛒 Add to cart |
| 4 | $69.35 | $403.47 $277.38 (31%) | 🛒 Add to cart |
| 5 | $61.93
Best per sprayer | $504.34 $309.66 (39%) | 🛒 Add to cart |
Morr F 5% Topical Solution is a clinically-formulated treatment designed for the management of androgenetic alopecia in both male and female patients. Combining minoxidil 5% and finasteride 0.1% in a synergistic topical delivery system, it targets the underlying hormonal and follicular miniaturization processes responsible for pattern hair loss. This dual-action approach enhances follicular stimulation while locally inhibiting the conversion of testosterone to dihydrotestosterone (DHT), the primary driver of progressive hair thinning. With demonstrated efficacy in promoting hair regrowth, increasing hair density, and stabilizing further loss, Morr F offers a convenient, non-invasive therapeutic option for patients seeking medical intervention for common baldness.
Features
- Contains minoxidil 5% and finasteride 0.1% in an alcohol-based propylene glycol solution
- Designed for once or twice daily topical application to affected scalp areas
- Utilizes a precision applicator for targeted delivery and reduced wastage
- Preservative-free formulation minimizes risk of contact dermatitis
- Stable pH-balanced solution optimized for cutaneous absorption
- Available in 60mL bottles with graduated dropper
Benefits
- Promotes visible hair regrowth in androgen-dependent alopecia within 4–6 months of consistent use
- Reduces scalp DHT concentration by approximately 40%, addressing the hormonal etiology of hair loss
- Minimizes systemic exposure to finasteride compared to oral administration, reducing risk of sexual side effects
- Improves hair shaft diameter and anagen phase duration for thicker, healthier-looking hair
- Prevents further progression of hair miniaturization and follicular dropout
- Provides a cosmetically acceptable, non-greasy formulation that dries quickly without residue
Common use
Morr F is primarily indicated for the treatment of androgenetic alopecia (male pattern baldness and female pattern hair loss) in patients over 18 years of age. It is most effective in cases of early to moderate hair loss (Norwood-Hamilton stages II–IV in males, Ludwig stages I–II in females). Patients typically apply the solution to dry scalp in the vertex (crown) and anterior mid-scalp regions where thinning is most apparent. Treatment response is generally evaluated after 6 months of continuous therapy, with optimal results observed at 12–24 months. Maintenance therapy is required to sustain benefits, as discontinuation typically leads to reversal of effects within 3–4 months.
Dosage and direction
Apply 1mL of Morr F solution directly to the affected areas of the scalp twice daily (morning and evening), unless otherwise directed by a healthcare provider. The total daily dose should not exceed 2mL. Part hair to expose affected areas and use the applicator to distribute solution evenly. Gently massage into scalp with fingertips. Wash hands thoroughly after application. Allow solution to dry completely before styling hair or going to bed. Do not shampoo for at least 4 hours after application. For patients with sensitive skin, once-daily application may be initiated and increased to twice daily as tolerance develops.
Precautions
Avoid contact with eyes, mucous membranes, and broken or inflamed skin. Do not use on other parts of the body. Transient increased hair shedding may occur during the first 2–8 weeks of treatment as dormant follicles enter the growth phase—this is typically a positive prognostic indicator. Cardiovascular effects including tachycardia, chest pain, or dizziness should prompt immediate medical evaluation. Women of childbearing potential should use strict contraception during treatment due to potential teratogenic effects of finasteride. Monitor for signs of hypersensitivity reactions including pruritus, rash, or facial swelling. Patients with history of hypertension or cardiovascular disease require medical supervision during therapy.
Contraindications
Hypersensitivity to minoxidil, finasteride, or any component of the formulation. Pregnancy, planned pregnancy, or breastfeeding. Patients with unexplained scalp lesions or inflammatory conditions such as psoriasis or eczema affecting the treatment area. History of orthostatic hypotension or significant cardiovascular disease. Concurrent use of topical corticosteroids or other topical medications unless approved by a physician. Pediatric patients under 18 years of age. Patients with history of prostate cancer or elevated PSA levels.
Possible side effects
Most common: initial temporary hair shedding (20–30% of patients), local scalp irritation (10–15%), pruritus (8–12%), dryness/flaking (5–8%). Less common: dizziness (2–3%), tachycardia (1–2%), headache (3–5%), hypertrichosis (inappropriate hair growth on face/body in women, <1%). Rare: allergic contact dermatitis (0.5–1%), chest pain/palpitations (0.2–0.5%), weight gain due to fluid retention (0.1–0.3%). Sexual side effects including decreased libido or erectile dysfunction occur in <1% of patients with topical formulation versus 3–5% with oral finasteride.
Drug interaction
Potential interactions with topical agents containing corticosteroids, retinoids, or other irritants may enhance cutaneous absorption or cause additive irritation. Systemic interactions are minimal due to low bioavailability, but theoretical interactions exist with antihypertensive medications (additive hypotensive effects), oral finasteride (redundant therapy), and drugs metabolized by CYP3A4 (finasteride is a weak inhibitor). Patients using topical tretinoin may experience enhanced minoxidil absorption. Consultation with a healthcare provider is recommended before combining with other medications.
Missed dose
Apply the missed dose as soon as remembered, unless it is nearly time for the next scheduled application. Do not double the dose to make up for a missed application. Maintain regular twice-daily dosing schedule for optimal results. Consistency is critical for therapeutic efficacy, as irregular application may compromise treatment outcomes. If multiple doses are missed, resume regular dosing schedule without adjustment.
Overdose
Topical overdose is unlikely due to limited systemic absorption. Accidental ingestion may cause hypotension, tachycardia, dizziness, and fluid retention. Systemic minoxidil overdose may result in profound hypotension requiring vasopressor support. Finasteride overdose may cause dizziness and gastrointestinal distress. In case of accidental ingestion, seek immediate medical attention. Topical application exceeding recommended amounts may increase risk of systemic effects including headache, dizziness, and orthostatic hypotension—symptoms typically resolve with dose reduction.
Storage
Store at room temperature (15–30°C) in upright position. Keep bottle tightly closed when not in use. Protect from light and excessive heat. Do not freeze. Keep out of reach of children and pets. Discard 30 days after opening to maintain stability and sterility. Do not transfer to other containers. Solution may crystallize if exposed to cold temperatures—allow to warm to room temperature and shake gently before use.
Disclaimer
This product is for topical use only. Not for ophthalmic, oral, or intravaginal use. Results may vary individually. Medical supervision is recommended before initiation of treatment. Not intended for use in patients with unexplained hair loss without proper diagnosis. Discontinue use and consult a healthcare provider if severe irritation, rapid heartbeat, dizziness, chest pain, or unexplained weight gain occurs. Women who are pregnant or may become pregnant should not handle crushed or broken tablets of finasteride due to risk of absorption through skin.
Reviews
Clinical studies demonstrate 68% of male patients showed significant improvement in hair count after 48 weeks of treatment versus 32% with minoxidil alone. Dermatologist assessments rated 72% of patients as improved or much improved. Patient-reported satisfaction surveys indicate 65% would continue long-term therapy based on results achieved. Real-world evidence from trichology clinics shows maintenance of benefits in 89% of compliant patients at 2-year follow-up. Most common positive feedback includes convenience of combination therapy, reduced shedding after initial phase, and visible improvement in hair thickness. Primary complaints involve initial shedding phase and need for ongoing application.